SymBio Pharmaceuticals Limited
4582
Rank in Stocks
#24596
SymBio Pharmaceuticals Limited engages in the and development, manufacturing... SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan.
Share Price
$0.36894253
Last synced: 2026-11-13
Market Cap
$30.98M
Change (1 day)
13.32%
Change (1 year)
-45.98%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade SymBio Pharmaceuticals Limited (4582)
Category
Healthcare
Operating Margin for SymBio Pharmaceuticals Limited (4582)
Operating Margin as of November 2026 TTM: -563.97%
According to SymBio Pharmaceuticals Limited's latest financial reports, its current operating margin (TTM) is -563.97%. At the end of 2025 the company had an operating margin of -339.59%.
Operating Margin history for SymBio Pharmaceuticals Limited from 2008 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -563.97% | 66.07% |
| 2025 | -339.59% | 114.85% |
| 2024 | -158.06% | 988.57% |
| 2023 | -14.52% | -174.01% |
| 2022 | 19.62% | 59.38% |
| 2021 | 12.31% | -108.16% |
| 2020 | -150.86% | -0.48% |
| 2019 | -151.59% | 118.90% |
| 2018 | -69.25% | -39.57% |
| 2017 | -114.60% | 27.59% |
| 2016 | -89.82% | -31.95% |
| 2015 | -131.99% | 98.00% |
| 2014 | -66.66% | -39.23% |
| 2013 | -109.69% | 26.14% |
| 2012 | -86.96% | -20.79% |
| 2011 | -109.79% | 159.80% |
| 2010 | -42.26% | 142.04% |
| 2009 | -17.46% | -314.23% |
| 2008 | 8.15% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 59.80% | -100.11% |
US
|
|
| 31.60% | -100.06% |
SE
|
|
| 30.13% | -100.05% |
FR
|
|
| 29.76% | -100.05% |
HK
|
|
| 31.11% | -100.06% |
IT
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about SymBio Pharmaceuticals Limited's operating margin
What is SymBio Pharmaceuticals Limited's operating margin?
SymBio Pharmaceuticals Limited's operating margin is -563.97%, as of Nov 2026.
What was SymBio Pharmaceuticals Limited's operating margin in 2025?
In 2025, SymBio Pharmaceuticals Limited's operating margin was -339.59%, compared with -158.06% in 2024.
How has SymBio Pharmaceuticals Limited's operating margin changed since 2020?
From 2020 to 2025, SymBio Pharmaceuticals Limited's operating margin was highest in 2022 (19.62%) and lowest in 2025 (-339.59%).
How does SymBio Pharmaceuticals Limited's operating margin compare with similar companies?
SymBio Pharmaceuticals Limited's operating margin (-563.97%) is lower than that of all 5 similar companies listed above. The highest among them is Royalty Pharma plc, with 59.80%.